Scientists have warned that an antibiotic-resistant strain of the bubonic plague could emerge and are developing a vaccine for the disease that has killed as many as 200 million people throughout ...

As noted above, the licensing of pneumonic plague vaccines will rely on efficacy data from animal studies and safety data from human trials. In addition, licensure will require assays that bridge ...

A vaccine for the bubonic plague is currently in development as the potential risk of a pandemic remains. To date, there is no cure for the disease, which claimed millions of lives during the 14th ...

The company also secured a $30 million contract with the U.S. Department of Defense to advance its plague vaccine program. The financial growth strengthens Dynavax’s market position, allowing it ...

The prairie dog caught in Trap 69 was angry. And who could blame her? After waking up in her burrow on a mid-September ...

Plague vaccine program: Dynavax is developing a plague (rF1V) vaccine candidate adjuvanted with CpG 1018® in collaboration with, and fully funded by, the U.S. Department of Defense (DoD).

Lastly, vaccine hesitancy could plague vaccine-focused firms like Moderna if new concerns about safety issues begin to emerge from the firm's novel mRNA vaccines. We model this into our demand ...

Republicans on the Senate Finance Committee voted to move forward with Trump's nominee to run Health and Human Services (HHS) ...

Rappuoli notes that similar problems of poor efficacy in the elderly also plague vaccines targeting other diseases. “Influenza is the tip of the iceberg,” he says.” He imagines that ...

We currently lack a safe, effective and licensed vaccine for pneumonic plague, which is nearly always fatal and has been weaponized. Yersinia pestis overcomes host defense, in a large part ...

Methane expelled by livestock belching and farting contributes about 15% of global emissions each year, UN estimates show. It ...